SCHEMBL4746461

SCHEMBL4746461

Cc1ccc2c(c1)c(-c1c3ccccc3c(-c3cc4c5ccc(C)c6c5c(cc4c4ccc(C)cc34)-c3ncccc3-6)c3ccccc13)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 1/20 0.33
BCHE P06276 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
AGTR1 P30556 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CCR1 P32246 1/20 0.31
CCR8 P51685 1/20 0.31
GSK3A P49840 1/20 0.31
GSK3B P49841 1/20 0.31
CTSL P07711 1/20 0.31
PTPRC P08575 1/20 0.31
CTSS P25774 1/20 0.31
PTPN13 Q12923 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746466 0.96 TOP2A (0.32) TOP2ABCHEKDM4EMEN1NPC1
SCHEMBL4746409 0.93 PDK2 (0.33) TOP2ABCHEKDM4EMEN1NPC1
SCHEMBL4746394 0.92 MEN1 (0.32) TOP2ABCHEKDM4EMEN1NPC1
SCHEMBL4746272 0.91 MAPT (0.32) TOP2ABCHEKDM4EMEN1NPC1
SCHEMBL4745985 0.91 BCHE (0.33) TOP2ABCHECTSLPTPRCCTSS
SCHEMBL4745945 0.90 HPRT1 (0.37) TOP2ABCHEMAPTMAPK1SMN1; SMN2
SCHEMBL4745849 0.90 CCR1 (0.35) TOP2ABCHEKDM4EMEN1NPC1
SCHEMBL4745982 0.90 ALDH1A1 (0.34) TOP2ABCHEKDM4EMEN1NPC1
SCHEMBL4746339 0.89 DHODH (0.36) BCHEKDM4EMEN1NPC1MAPT
SCHEMBL4745860 0.89 MAOA (0.35) TOP2ABCHEKDM4EMAPTCCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 TOP2A 1041/4885BCHE 376/4885KDM4E 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.